These include dual-target CARs that require recognition of two tumor-associated antigens (e.g., B7-H3 and GPC3, or EGFRvIII and mesothelin) or use AND-/NOT-gating logic to fine-tune activation thresholds. Here, CD276 is linked to neoplasm.